Dr. Reddy's Laboratories Ltd.

Link copied
Case Copied 5 min read

IP AUSTRALIA

AUSTRALIAN PATENT OFFICE

Dr. Reddy's Laboratories Ltd. [2014] APO 47

Patent Application:                2009314512

Title:Lenalidomide solvates and processes

Patent Applicant:                   Dr. Reddy's Laboratories Ltd.

Delegate:  Dr S.D. Barker

Decision Date:  1 July 2014

Hearing Date:  Submissions were due by 14 June 2014, but were not provided

Catchwords:  PATENTS – re-examination of application following withdrawal of opposition – objection of lack of novelty – citation discloses preparation of hemihydrate of lenalinomide – no reasonable prospects of the applicant amending the specification – application refused

Representation:  Patent applicant:  Freehills Patent Attorneys

IP AUSTRALIA

AUSTRALIAN PATENT OFFICE

Patent Application:                2009314512

Title:Lenalidomide solvates and processes

Patent Applicant:                   Dr. Reddy's Laboratories Ltd.

Date of Decision:                   1 July 2014

DECISION

I refuse to accept the request and specification.

REASONS FOR DECISION

  1. Patent application number 2009314512 was filed as an application under the Patent Cooperation Treaty on 11 March 2009.  The applicant is Dr. Reddy's Laboratories Ltd. (Dr Reddy's).  The application was examined and accepted by the Commissioner, and subsequently opposed by Celgene Corporation (Celgene).  Celgene withdrew the opposition on 12 November 2013.  In the light of documents mentioned in the statement of grounds and particulars, the Commissioner decided to re-examine the application, and issued a report on 5 December 2013, and a subsequent report on 5 March 2014.  Dr Reddy's did not respond to the second report, and the Commissioner decided to determine the re-examination on the basis of written submissions.  Dr Reddy's did not provide any submissions.

    The re-examination

  2. The Examiner reported that claims 1 – 3, 5, 6 and 16 lack novelty in the light of WO 2009/114601 (D1).  Dr Reddy's is also the applicant in relation to D1.

  3. Clearly there are claims that the Examiner considers possess novelty, and a patent could be granted if the claims were amended to exclude the subject matter that lacks novelty.  Dr Reddy's has not provided submissions disputing the objection, and has not proposed any amendment to attempt to overcome the objections.

  4. In this situation, it appears that Dr Reddy's has lost interest in further prosecuting the application.  Consequently, if I find that the objection is validly raised, there are no reasonable prospects of the objection being overcome.  There would be no point in giving Dr Reddy's a further opportunity to amend, and I should proceed to refuse the application.

    Status of the application

  5. A continuation fee was due on 11 March 2014, but has not yet been paid.  Pursuant to regulation 13.3(1A) if the fee is paid within 6 months of that date (and the additional fee is paid) then the time for payment of the fee is taken to be extended until the fee is paid.  Consequently, this application has a status that is often referred to as in a "state of lapse".  It is apparent from the decision in Miles v Commissioner [2013] FCA 1017, 306 ALR 349 that an application in a state of lapse can be refused.

    The specification

  6. The specification relates to the…

CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read Dr. Reddy's Laboratories Ltd. and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[2014] APO 47
Decision Date

CaseChat Overview and Summary

The case involves a patent application for lenalidomide solvates and processes filed by Dr. Reddy's Laboratories Ltd. The application was subject to a re-examination by the Australian Patent Office following the withdrawal of an opposition by Celgene Corporation. The Commissioner issued two reports, the second of which was not responded to by Dr. Reddy's, leading to the determination of the re-examination on written submissions. Dr. Reddy's did not provide any submissions and has not proposed any amendments to address the objections raised by the Examiner.

The legal issues before the court were whether the objection of lack of novelty was validly raised and whether there were reasonable prospects of the objection being overcome. The Examiner had raised the objection that claims 1 to 3, 5, 6, and 16 of the application lacked novelty in light of a prior art document (D1). The Commissioner found that the objection was validly raised and that there were no reasonable prospects of the objection being overcome. The application was considered to be in a "state of lapse" due to an unpaid continuation fee, and the Commissioner concluded that there was no point in giving Dr. Reddy's a further opportunity to amend.

The court found that the objection of lack of novelty was validly raised, as the prior art document disclosed the preparation of a hemihydrate of lenalidomide, which is a solvate. The document contained clear and unmistakable directions to do what the patentee claimed to have invented, satisfying the reverse infringement test. The Commissioner concluded that the objection was validly raised and there were no reasonable prospects of overcoming the objection. Therefore, the application should be refused.

The court upheld the Commissioner's decision and refused the patent application.

Orders

Orders of the court

Background

Background to the litigation

Evidence

Evidence Before The Court

Decision

Reasons for decision

Ratio Decidendi

Legal Principle Established